Fertility and Sterility
Volume 91, Issue 6 , Pages 2419-2425 , June 2009

Serum inhibin B during controlled ovarian hyperstimulation: an additional criterion for deciding whether to proceed with egg retrieval

  • Christine Decanter, M.D.

      Affiliations

    • Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire (CHRU), Lille, France
    • Faculty of Medicine, Université de Lille II, Lille, France
    • Corresponding Author InformationReprint requests: Christine Decanter, M.D., Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, CHRU, 59037 Lille, France (FAX: 33-3-20-44-41-84).
    • ,
  • Pascal Pigny, M.D.

      Affiliations

    • Laboratory of Endocrinology, Parc Eurasante, CHRU, Lille, France
    • ,
  • Catherine Lefebvre, M.D.

      Affiliations

    • Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire (CHRU), Lille, France
    • Faculty of Medicine, Université de Lille II, Lille, France
    • ,
  • Patricia Thomas, M.D.

      Affiliations

    • Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire (CHRU), Lille, France
    • Faculty of Medicine, Université de Lille II, Lille, France
    • ,
  • Maryse Leroy, M.D.

      Affiliations

    • Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire (CHRU), Lille, France
    • Faculty of Medicine, Université de Lille II, Lille, France
    • ,
  • Didier Dewailly, M.D.

      Affiliations

    • Department of Endocrine Gynecology and Reproductive Medicine, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire (CHRU), Lille, France
    • Faculty of Medicine, Université de Lille II, Lille, France

Received 10 January 2008 ,Revised 13 March 2008 ,Accepted 14 March 2008.

References 

  1. Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril. 2001;76:1185–1190
  2. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril. 2003;79:1091–1097
  3. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:1401–1405
  4. Welt CK, Schneyer AL. Differential regulation of inhibin B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab. 2001;86:330–336
  5. Josso N, di Clemente N, Gouedard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol. 2001;179:25–32
  6. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83
  7. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril. 1997;67:110–114
  8. Danforth DR, Arbogast LK, Mroueh J, Kim MH, Kennard EA, Seifer DB, et al. Dimeric inhibin: a direct marker of ovarian aging. Fertil Steril. 1998;70:119–123
  9. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–3071
  10. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468–471
  11. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18:323–327
  12. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131:1–9
  13. Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12:695–703
  14. Hall JE, Welt CK, Cramer DW. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod. 1999;14:409–415
  15. Tinkanen H, Blauer M, Laippala P, Tuohimaa P, Kujansuu E. Prognostic factors in controlled ovarian hyperstimulation. Fertil Steril. 1999;72:932–936
  16. Creus M, Penarrubia J, Fabregues F, Vidal E, Carmona F, Casamitjana R, et al. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod. 2000;15:2341–2346
  17. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER. Predictors of poor ovarian response in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril. 2002;77:328–336
  18. Seifer DB, Maclaughlin DT. Müllerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007;88:539–546
  19. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–1329
  20. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-müllerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?. BJOG. 2005;112:1384–1390
  21. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril. 2007;87:223–226
  22. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007;22:766–771
  23. Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod. 2007;22:2414–2421
  24. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod. 2005;20:915–922
  25. Hehenkamp WJK, Looman CWN, Themmen APN, de Jong FH, te velde ER, Broekmans FJM. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057–4063
  26. Fanchin R, de Ziegler D, Olivennes F, Taieb J, Dzik A, Frydman R. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting ‘poor responders’ in in-vitro fertilization. Hum Reprod. 1994;9:1607–1611
  27. Wachs DS, Coffler MS, Malcom PJ, Chang RJ. Serum anti-müllerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab. 2007;92:1871–1874
  28. Fanchin R, Schonauer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod. 2003;18:328–332
  29. Kwee J, Elting MW, Schats R, Bezemer PD, Lambalk CB, Schoemaker J. Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. Hum Reprod. 2003;18:1422–1427
  30. Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA, Seifer DB. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertil Steril. 2000;74:1114–1117
  31. Elting MW, Kwee J, Schats R, Rekers-Mombarg LT, Schoemaker J. The rise of estradiol and inhibin B after acute stimulation with follicle-stimulating hormone predict the follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries. J Clin Endocrinol Metab. 2001;86:1589–1595
  32. Yong PY, Baird DT, Thong KJ, McNeilly AS, Anderson RA. Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. Hum Reprod. 2003;18:35–44
  33. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Müllerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20:3178–3183
  34. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718
  35. Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te Velde ER. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril. 1999;72:845–851
  36. Porchet HC, le Cotonnec JY, Loumaye E. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril. 1994;61:687–695
  37. Penarrubia J, Balasch J, Fabregues F, Carmona F, Casamitjana R, Moreno V, et al. Day 5 inhibin B serum concentrations as predictors of assisted reproductive technology outcome in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment. Hum Reprod. 2000;15:1499–1504
  38. Eldar-Geva T, Robertson DM, Cahir N, Groome N, Gabbe MP, Maclachlan V, et al. Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone. J Clin Endocrinol Metab. 2000;85:607–613
  39. Eldar-Geva T, Margalioth EJ, Ben-Chetrit A, Gal M, Robertson DM, Healy DL, et al. Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. Hum Reprod. 2002;17:2331–2337
  40. Fawzy M, Lambert A, Harrison RF, Knight PG, Groome N, Hennelly B, et al. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod. 2002;17:1535–1543
  41. Urbancsek J, Hauzman E, Klinga K, Rabe T, Papp Z, Strowitzki T. Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome. Fertil Steril. 2005;83:341–348
  42. le Contonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril. 1994;61:679–686

 C.D. has nothing to disclose. P.P. has nothing to disclose. C.L. has nothing to disclose. P.T. has nothing to disclose. M.L. has nothing to disclose. D.D. has nothing to disclose.

PII: S0015-0282(08)00704-8

doi: 10.1016/j.fertnstert.2008.03.037

Fertility and Sterility
Volume 91, Issue 6 , Pages 2419-2425 , June 2009

Article Tools

* Image Usage & Resolution